

To Whom It May Concern

Ref.: **Clinical Study NGAM-03:** "PROSPECTIVE, PARALLEL GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMISED, MULTICENTRE, ADAPTIVE, TWO-STAGE PHASE II/III STUDY EVALUATING SAFETY AND EFFICACY OF THREE DIFFERENT DOSAGES OF NEWGAM IN PATIENTS WITH CHRONIC INFLAMMATORY DEMYELINATING POLYRADICULONEUROPATHY (POINT TRIAL)"

Vienna, 22 June 2017

Octapharma Pharmazeutika Produktionsges.m.b.H. herewith confirms that the clinical study NGAM-03 with Newgam 10% in CIDP patients has not been performed. This decision was made by the Octapharma Board and was driven on priority changes in product development.

At the time of termination of the study two patients attended the screening visit, but none passed into the treatment phase. No study drug was given to any patient. As a consequence no data have been collected and therefore no results can be presented.

OCTAPHARMA Pharmazeutika Produktionsges.m.b.H.


Dr. Wolfgang Frenzel *
Medical Director

FRENZEL 29. AUG. 2017

Dr. Eva Turpel-Kantor
Clinical Project Manager


E. Turpel-Kantor 22. JUNI 2017

Octapharma Pharmazeutika
Produktionsges.m.b.H.
Oberlaaer Straße 235
A-1100 Wien

Tel.: (+43-1) 610 32-0
Fax: (+43-1) 610 32-9300

Rechtsform: Gesellschaft m.b.H.
Sitz des Unternehmens: Wien
UID-Nr: ATU 14253608
Firmenbuchnummer: FN 63568 h
Firmenbuchgericht: HG Wien
DVR-Nr: 0599379